바이오시밀러 시장 규모, 점유율, 동향 분석 보고서 : 약물 종류별, 적응증별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Biosimilars Market Summary

The global biosimilars market size was estimated at USD 39.59 billion in 2025 and is projected to reach USD 151.58 billion by 2033, growing at a CAGR of 18.44% from 2026 to 2033. The cost-effectiveness of biosimilar drugs and the prevalence of chronic disorders globally are major factors contributing to market growth.

The market continues to gain momentum as these products are comparatively easier to develop than novel biologics, requiring lower research and development investment while delivering comparable clinical outcomes. Reduced development timelines and manufacturing efficiencies translate into lower production costs, enabling competitive pricing and attractive margins for manufacturers. As demand for cost-effective biologic therapies rises across both developed and emerging markets, producers are increasingly shifting strategic focus toward biosimilars to enhance portfolio profitability. Although biosimilars may exhibit minor differences in excipients or formulation components, they are evaluated to ensure no clinically meaningful differences from reference biologics in terms of safety, purity, and efficacy, supporting their broader adoption across therapeutic areas.

Regulatory frameworks play a central role in building confidence and accelerating market uptake. The U.S. Food and Drug Administration requires biosimilar applicants to demonstrate high similarity to the reference biologic through extensive analytical characterization, pharmacokinetic comparability, and clinical evidence where required. These regulatory pathways are designed to ensure patient safety while avoiding unnecessary duplication of clinical trials, thereby reducing development risk and cost. Such stringent yet efficient approval processes have strengthened physician and payer trust in biosimilars, contributing to expanding market share in oncology, immunology, and chronic disease management.

A notable 2025 commercial instance reinforcing this trend is the U.S. launch of Wezlana by Amgen, a biosimilar referencing Stelara for autoimmune indications. This launch marked a significant milestone in high-value immunology biosimilars, demonstrating manufacturers' ability to compete in complex monoclonal antibody segments. The entry of Wezlana is expected to improve treatment affordability in dermatology and gastroenterology while intensifying price competition within the ustekinumab market, thereby supporting overall biosimilars revenue growth in 2025.

Growing regulatory approvals and investment activity further illustrate the market's maturity. The U.S. FDA approved multiple oncology-related biosimilars in recent years, translating into commercial launches that continue to shape the competitive landscape. In parallel, manufacturers are scaling research and development investments to strengthen future pipelines. For instance, Biocon Biologics announced plans to increase R&D spending to advance its biosimilar portfolio, reflecting industry-wide confidence in long-term demand. Collectively, these developments highlight a sustained boom in biosimilar development and commercialization, positioning the market for steady growth over the forecast period.

Global Biosimilars Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biosimilars market report based on drug class, indication, end use, and region:

• Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
• Monoclonal Antibodies (mAbs)
• Growth Factors & Hematopoietic Agents
• Insulin & Analogues
• Osteoporosis / Bone Metabolism Agents
• Others
• Indication Outlook (Revenue, USD Billion, 2021 - 2033)
• Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
• Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
• Diabetes Mellitus (Type 1 & Type 2)
• Ophthalmic Disorders (Wet AMD, DME, RVO)
• Hematologic / Rare Blood Disorders
• Others
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals
• Specialty Pharmacies
• Online & Retail Channels
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Indication
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biosimilars Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis

Chapter 4. Biosimilars Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2025 & 2033
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
• 4.4. Monoclonal Antibodies (mAbs)
  • 4.4.1. Monoclonal Antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.5. Growth Factors & Hematopoietic Agents
  • 4.5.1. Growth Factors & Hematopoietic Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.6. Insulin & Analogues
  • 4.6.1. Insulin & Analogues Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.7. Osteoporosis / Bone Metabolism Agents
  • 4.7.1. Osteoporosis / Bone Metabolism Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. Biosimilars Market: Indication Business Analysis

• 5.1. Indication Market Share, 2025 & 2033
• 5.2. Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
• 5.4. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
  • 5.4.1. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.5. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
  • 5.5.1. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.6. Diabetes Mellitus (Type 1 & Type 2)
  • 5.6.1. Diabetes Mellitus (Type 1 & Type 2) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.7. Ophthalmic Disorders (Wet AMD, DME, RVO)
  • 5.7.1. Ophthalmic Disorders (Wet AMD, DME, RVO) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.8. Hematologic / Rare Blood Disorders
  • 5.8.1. Hematologic / Rare Blood Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.9. Others
  • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Biosimilars Market: End Use Business Analysis

• 6.1. End Use Market Share, 2025 & 2033
• 6.2. End Use Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
• 6.4. Hospitals
  • 6.4.1. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.5. Specialty Pharmacies
  • 6.5.1. Specialty Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.6. Online & Retail Channels
  • 6.6.1. Online & Retail Channels Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Biosimilars Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Biosimilars Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Type Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Type Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. Canada Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Type Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.5. Europe
  • 7.5.1. Europe Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Type Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. UK Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Type Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Type Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Type Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Type Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Type Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Type Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Type Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Type Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Type Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Type Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Type Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Type Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Type Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.7. Latin America
  • 7.7.1. Latin America Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Type Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Brazil Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Type Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. Argentina Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Type Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Type Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Type Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Type Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Amgen Inc
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. F Hoffman-La Roche Ltd.
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Sandoz International GmbH
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Dr. Reddy's Laboratories Ltd.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Teva Pharmaceutical Industries Ltd.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Pfizer Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Samsung Biopis
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Biocon
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Viatris Inc.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Celltrion Healthcare Co., Ltd.
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. AbbVie Inc.
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives